Standard

ДОЗОИНТЕНСИВНАЯ НЕОАДЪЮВАНТНАЯ ХИМИОТЕРАПИЯ В КОМБИНИРОВАННОМ ЛЕЧЕНИИ МЕСТНОРАСПРОСТРАНЕННОГО РАКА ШЕЙКИ МАТКИ : ОПЫТ И ПЕРСПЕКТИВЫ. / Berlev, I. V.; Bondarev, N. E.; Urmancheeva, A. F.; Mikaya, N. A.; Mishchenko, A. V.; Petrova, A. S.; Semiglazova, T. Yu; Artemieva, A. S.; Bashlyk, V. O.; Ulrikh, E. A.; Guseinov, K. D.; Bezhanova, E. G.; Mkrtchyan, G. B.; Nekrasova, E. A.; Smirnova, O. V.

в: Voprosy Onkologii, Том 63, № 4, 2017, стр. 614-621.

Результаты исследований: Научные публикации в периодических изданиях › статья › Рецензирование

Harvard

Berlev, IV, Bondarev, NE, Urmancheeva, AF, Mikaya, NA, Mishchenko, AV, Petrova, AS, Semiglazova, TY, Artemieva, AS, Bashlyk, VO, Ulrikh, EA, Guseinov, KD, Bezhanova, EG, Mkrtchyan, GB, Nekrasova, EA & Smirnova, OV 2017, 'ДОЗОИНТЕНСИВНАЯ НЕОАДЪЮВАНТНАЯ ХИМИОТЕРАПИЯ В КОМБИНИРОВАННОМ ЛЕЧЕНИИ МЕСТНОРАСПРОСТРАНЕННОГО РАКА ШЕЙКИ МАТКИ: ОПЫТ И ПЕРСПЕКТИВЫ', Voprosy Onkologii, Том. 63, № 4, стр. 614-621.

APA

Berlev, I. V., Bondarev, N. E., Urmancheeva, A. F., Mikaya, N. A., Mishchenko, A. V., Petrova, A. S., Semiglazova, T. Y., Artemieva, A. S., Bashlyk, V. O., Ulrikh, E. A., Guseinov, K. D., Bezhanova, E. G., Mkrtchyan, G. B., Nekrasova, E. A., & Smirnova, O. V. (2017). ДОЗОИНТЕНСИВНАЯ НЕОАДЪЮВАНТНАЯ ХИМИОТЕРАПИЯ В КОМБИНИРОВАННОМ ЛЕЧЕНИИ МЕСТНОРАСПРОСТРАНЕННОГО РАКА ШЕЙКИ МАТКИ: ОПЫТ И ПЕРСПЕКТИВЫ. Voprosy Onkologii, 63(4), 614-621.

Vancouver

Berlev IV, Bondarev NE, Urmancheeva AF, Mikaya NA, Mishchenko AV, Petrova AS и пр. ДОЗОИНТЕНСИВНАЯ НЕОАДЪЮВАНТНАЯ ХИМИОТЕРАПИЯ В КОМБИНИРОВАННОМ ЛЕЧЕНИИ МЕСТНОРАСПРОСТРАНЕННОГО РАКА ШЕЙКИ МАТКИ: ОПЫТ И ПЕРСПЕКТИВЫ. Voprosy Onkologii. 2017;63(4):614-621.

Author

Berlev, I. V. ; Bondarev, N. E. ; Urmancheeva, A. F. ; Mikaya, N. A. ; Mishchenko, A. V. ; Petrova, A. S. ; Semiglazova, T. Yu ; Artemieva, A. S. ; Bashlyk, V. O. ; Ulrikh, E. A. ; Guseinov, K. D. ; Bezhanova, E. G. ; Mkrtchyan, G. B. ; Nekrasova, E. A. ; Smirnova, O. V. / ДОЗОИНТЕНСИВНАЯ НЕОАДЪЮВАНТНАЯ ХИМИОТЕРАПИЯ В КОМБИНИРОВАННОМ ЛЕЧЕНИИ МЕСТНОРАСПРОСТРАНЕННОГО РАКА ШЕЙКИ МАТКИ : ОПЫТ И ПЕРСПЕКТИВЫ. в: Voprosy Onkologii. 2017 ; Том 63, № 4. стр. 614-621.

BibTeX

@article{8df5d5d32bd041368e4e22d02e57cede,
title = "ДОЗОИНТЕНСИВНАЯ НЕОАДЪЮВАНТНАЯ ХИМИОТЕРАПИЯ В КОМБИНИРОВАННОМ ЛЕЧЕНИИ МЕСТНОРАСПРОСТРАНЕННОГО РАКА ШЕЙКИ МАТКИ: ОПЫТ И ПЕРСПЕКТИВЫ",
abstract = "In 24 patients (mean age 48 years) with locally advanced cervical cancer there were studied the efficacy and toxicity of 3 cycles of neoadjuvant dose-intensive chemotherapy with cisplatin (75 mg/m2) and doxorubicin (35 mg/m2) administered intravenously on the first day of a two- week cycle with the support of colony-stimulating factors. An important criterion for the inclusion in this study of patients with locally advanced cervical cancer (Tlb2-2bN0-lM0) was the absence of infiltration of the anterior parameters according to the gynecological examination and MRI studies. An objective response to treatment was registered in 72.7% of cases. Progression of the disease was not detected in any case. Conducting neoadjuvant drug therapy allowed performing radical surgical intervention in 95.4% of patients. The pathomorphlogical response of tumor of varying severity was 40.9%. In 9.1% complete clinical regression of tumor was confirmed by a complete pathomor-phological response (CR). The dose-intensive regimen of chemotherapy did not lead to a significant increase of complications on the drug and surgical stages. An analysis showed that dose-intensive neoadjuvant chemotherapy is a highly effective method in treatment for locally advanced cervical cancer.",
keywords = "CR, Dose-intensive neoadjuvant chemotherapy, Locally advanced cervical cancer, Pathomorphological response",
author = "Berlev, {I. V.} and Bondarev, {N. E.} and Urmancheeva, {A. F.} and Mikaya, {N. A.} and Mishchenko, {A. V.} and Petrova, {A. S.} and Semiglazova, {T. Yu} and Artemieva, {A. S.} and Bashlyk, {V. O.} and Ulrikh, {E. A.} and Guseinov, {K. D.} and Bezhanova, {E. G.} and Mkrtchyan, {G. B.} and Nekrasova, {E. A.} and Smirnova, {O. V.}",
year = "2017",
language = "русский",
volume = "63",
pages = "614--621",
journal = "Вопросы онкологии",
issn = "0507-3758",
publisher = "Медицина",
number = "4",

}

RIS

TY - JOUR

T1 - ДОЗОИНТЕНСИВНАЯ НЕОАДЪЮВАНТНАЯ ХИМИОТЕРАПИЯ В КОМБИНИРОВАННОМ ЛЕЧЕНИИ МЕСТНОРАСПРОСТРАНЕННОГО РАКА ШЕЙКИ МАТКИ

T2 - ОПЫТ И ПЕРСПЕКТИВЫ

AU - Berlev, I. V.

AU - Bondarev, N. E.

AU - Urmancheeva, A. F.

AU - Mikaya, N. A.

AU - Mishchenko, A. V.

AU - Petrova, A. S.

AU - Semiglazova, T. Yu

AU - Artemieva, A. S.

AU - Bashlyk, V. O.

AU - Ulrikh, E. A.

AU - Guseinov, K. D.

AU - Bezhanova, E. G.

AU - Mkrtchyan, G. B.

AU - Nekrasova, E. A.

AU - Smirnova, O. V.

PY - 2017

Y1 - 2017

N2 - In 24 patients (mean age 48 years) with locally advanced cervical cancer there were studied the efficacy and toxicity of 3 cycles of neoadjuvant dose-intensive chemotherapy with cisplatin (75 mg/m2) and doxorubicin (35 mg/m2) administered intravenously on the first day of a two- week cycle with the support of colony-stimulating factors. An important criterion for the inclusion in this study of patients with locally advanced cervical cancer (Tlb2-2bN0-lM0) was the absence of infiltration of the anterior parameters according to the gynecological examination and MRI studies. An objective response to treatment was registered in 72.7% of cases. Progression of the disease was not detected in any case. Conducting neoadjuvant drug therapy allowed performing radical surgical intervention in 95.4% of patients. The pathomorphlogical response of tumor of varying severity was 40.9%. In 9.1% complete clinical regression of tumor was confirmed by a complete pathomor-phological response (CR). The dose-intensive regimen of chemotherapy did not lead to a significant increase of complications on the drug and surgical stages. An analysis showed that dose-intensive neoadjuvant chemotherapy is a highly effective method in treatment for locally advanced cervical cancer.

AB - In 24 patients (mean age 48 years) with locally advanced cervical cancer there were studied the efficacy and toxicity of 3 cycles of neoadjuvant dose-intensive chemotherapy with cisplatin (75 mg/m2) and doxorubicin (35 mg/m2) administered intravenously on the first day of a two- week cycle with the support of colony-stimulating factors. An important criterion for the inclusion in this study of patients with locally advanced cervical cancer (Tlb2-2bN0-lM0) was the absence of infiltration of the anterior parameters according to the gynecological examination and MRI studies. An objective response to treatment was registered in 72.7% of cases. Progression of the disease was not detected in any case. Conducting neoadjuvant drug therapy allowed performing radical surgical intervention in 95.4% of patients. The pathomorphlogical response of tumor of varying severity was 40.9%. In 9.1% complete clinical regression of tumor was confirmed by a complete pathomor-phological response (CR). The dose-intensive regimen of chemotherapy did not lead to a significant increase of complications on the drug and surgical stages. An analysis showed that dose-intensive neoadjuvant chemotherapy is a highly effective method in treatment for locally advanced cervical cancer.

KW - CR

KW - Dose-intensive neoadjuvant chemotherapy

KW - Locally advanced cervical cancer

KW - Pathomorphological response

UR - http://www.scopus.com/inward/record.url?scp=85033227327&partnerID=8YFLogxK

M3 - статья

AN - SCOPUS:85033227327

VL - 63

SP - 614

EP - 621

JO - Вопросы онкологии

JF - Вопросы онкологии

SN - 0507-3758

IS - 4

ER -

ID: 88743365